For the Inventor, By the Inventor

Enter assignee name

Fuso Pharmaceutical Industries, Ltd.

USPTO Granted Patents = 108

% Expired Patents = 40.7

CIPO Patents = 9

EPO Patents = 39

Forward Citations = 695

Loading Chart...

Loading Chart...

156 inventors (with patents filed for the assignee):

Akio Matsuhisa (14 out of 16 patents)

Nobutaka Wakamiya (14 out of 14 patents)

Keiichi Yamamoto (11 out of 34 patents)

4. Masahiro Asakura (10 out of 11 patents)

5. Shinji Yamasaki (9 out of 9 patents)

6. Hiroyuki Keshi (9 out of 9 patents)

7. Yasuhiko Suzuki (8 out of 8 patents)

8. Hirotsugu Uehara (8 out of 9 patents)

9. Akira Okui (7 out of 7 patents)

10. Katsuya Kominami (7 out of 7 patents)

11. Nozomi Yamaguchi (7 out of 14 patents)

12. Shinichi Mitsui (7 out of 7 patents)

13. Hidetoshi Uemura (6 out of 6 patents)

14. Soji Eda (6 out of 7 patents)

15. Tsuneya Ohno (6 out of 9 patents)

Core Competencies:

Therapeutic Drugs

Anti-PD-L1 Antibody

Lipid-Peroxidation

Detection Methods

Calcium Channel Inhibitor

High Purity Heparin

Gene Transfer

Peptide Derivative

Scavenger Receptor

Protein Expression Vector

Monoclonal Antibody

Ischemic Diseases

108 patents: Sort by Forward Citations

1. 12678431 - Pharmaceutical composition for treatment of dementia and cerebrovascular disorders (2026-07-14),

2. 12472299 - Reservoir assembly for providing cardioplegic solution containing bicarbonate ion, and method for manufacturing the same (2025-11-18),

3. 12306164 - Therapeutic drug for lipid-peroxidation-induced diseases and screening method for therapeutic drugs for lipid-peroxidation-induced diseases (2025-05-20),

4. 11781146 - Vector including a translation-impaired dihydrofolate reductase gene cassette and ubiquitously acting chromatin opening element (2023-10-10),

5. 11725002 - Detection reagents and kit for identifying oxidized state and glycated state of low-density lipoproteins (2023-08-15),

6. 11697686 - Anti-PD-L1 antibody for detecting PD-L1 (2023-07-11),

7. 11609238 - Method for detecting a radical compound derived from a lipid and a compound derived from the radical compound (2023-03-21),

8. 11591297 - Compound having PD-L1 expression-suppressing action (2023-02-28),

9. 11519893 - Therapeutic drug for lipid-peroxidation-induced diseases and screening method for therapeutic drugs for lipid-peroxidation-induced diseases (2022-12-06),

10. 11479537 - T-type calcium channel inhibitor (2022-10-25),

11. 11312773 - Anti-PD-L1 antibody (2022-04-26),

12. 11198730 - Anti-LAG-3 antibody (2021-12-14),

13. 11193162 - Nucleic acid detection or quantification method using mask oligonucleotide, and device for same (2021-12-07),

14. 11174310 - Disulfide-type HMGB1-specific antibody, method for measuring disulfide-type HMGB1 and kit for said measurement, and measurement method capable of quantitating all of HMGB1 molecules including reduced HMGB1, disulfide-type HMGB1 and thrombin-cleavable HMGB1 and kit for said measurement (2021-11-16),

15. 11160286 - Method for producing disinfected liver (2021-11-02),

Company Overview

Fuso Pharmaceutical Industries, Ltd., based in Osaka, Japan, specializes in the development and manufacturing of innovative therapeutic drugs. The company focuses on advanced pharmaceutical technologies, including anti-PD-L1 antibodies and high purity heparin, addressing critical medical needs. Fuso is also engaged in research related to lipid-peroxidation detection methods, calcium channel inhibitors, gene transfer techniques, and peptide derivatives, contributing to the advancement of healthcare solutions in the pharmaceutical sector.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

108 Patents

#118 in Osaka

#1,071 in Japan

#7,281 in the World

Fuso Pharmaceutical Industries, Ltd.

Forward Citations = 695

156 inventors:

Akio Matsuhisa (14 out of 16 patents)

Nobutaka Wakamiya (14 out of 14 patents)

Keiichi Yamamoto (11 out of 34 patents)

4. Masahiro Asakura (10 out of 11 patents)

5. Shinji Yamasaki (9 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Fuso Pharmaceutical Industries, Ltd.. Retrieved from https://idiyas.com/company/fuso-pharmaceutical-industries

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…